earnings
confidence high
sentiment negative
materiality 0.70
Azitra Q3 net loss widens to $2.8M; cash $1.4M; first patient dosed in ATR-04 Ph1/2 trial
Azitra, Inc.
2025-Q3 EPS
reported -$3.06
vs consensus -$0.79
▼ miss
(-287.1%)
- Net loss of $2.8M for Q3 2025, compared to $1.0M in Q3 2024.
- Cash and equivalents $1.4M as of Sept 30, 2025; raised $2.8M gross via equity line from Alumni Capital.
- Dosed first patient in Phase 1/2 trial for ATR-04 targeting EGFRi-associated rash; FDA Fast Track granted.
- Presented positive preclinical data for ATR-01 (ichthyosis vulgaris) at BIO-Europe.
- R&D expenses $1.2M (up from $1.0M), G&A $1.6M (down from $1.9M) YoY.